Wyeth's Patent Loss Has Attys Focusing On Dosage
The Federal Circuit's holding that a Pfizer unit's cancer treatment patents are invalid highlights the risk of including dosages in patents without sufficient proof that those dosages work, attorneys say....To view the full article, register now.
Already a subscriber? Click here to view full article